# OnCo record decitabine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/decitabine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "decitabine" ;
  schema:name "Decitabine"@en ;
  schema:alternateName "5-aza-2'-deoxycytidine"@en, "Dacogen" ;
  schema:description "Decitabine (Dacogen) is an infusion that loosens the chemical silencing of genes in myelodysplastic syndromes and acute myeloid leukaemia, helping the bone marrow work again. An oral version combined with cedazuridine has its own record."@en ;
  schema:url <https://onco.cc/drugs/decitabine/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Decitabine> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=decitabine>, <https://www.cancer.gov/about-cancer/treatment/drugs/decitabine>, <https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Hypomethylating agent (DNA methyltransferase inhibitor)" ;
  onco:approval "US 2006: Myelodysplastic syndromes, all FAB subtypes and IPSS intermediate-1 to high risk", "EU 2012: Newly diagnosed de novo or secondary AML in adults 65 and over not candidates for standard induction" ;
  onco:related <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/drugs/azacitidine/> ;
  onco:cancers <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds-higher-risk/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:companies <https://onco.cc/companies/otsuka/> ;
  onco:trials <https://onco.cc/trials/nct05883956/>, <https://onco.cc/trials/nct04229979/>, <https://onco.cc/trials/nct02781883/> .